e-learning
resources
Vienna 2009
Monday, 14.09.2009
Aspects of clinical asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Impediments to the start of omalizumab in a small pulmonary practice
A. Redford, M. L. Zaremba, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America)
Source:
Annual Congress 2009 - Aspects of clinical asthma
Session:
Aspects of clinical asthma
Session type:
Thematic Poster Session
Number:
1974
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Redford, M. L. Zaremba, S. Ali, N. Shah, S. Reddy (Port Huron, United States Of America). Impediments to the start of omalizumab in a small pulmonary practice. Eur Respir J 2009; 34: Suppl. 53, 1974
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Respiratory sequelae of preterm birth across the life span
Related content which might interest you:
Barriers to the continued use of omalizumab in a small outpatient setting
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Reducing the use of inhaled corticosteroids in mild COPD patients treated in primary care by a training program in national guidelines and using a portable device to measure pulmonary function
Source: Eur Respir J 2005; 26: Suppl. 49, 294s
Year: 2005
Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Severe asthma and biologic therapies during COVID-19: supporting patients care with home administration of mepolizumab and omalizumab
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice
Source: Eur Respir J 2002; 20: Suppl. 38, 212s
Year: 2002
Challenges to compliance in new CPAP users
Source: Annual Congress 2009 - Continuous positive airway pressure therapy in obstructive sleep apnoea
Year: 2009
Effectiveness of pulmonary rehabilitation programs on persistent asthma.
Source: International Congress 2018 – Biomarkers for evaluating asthma
Year: 2018
Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation?
Source: International Congress 2019 – Hot topics in pulmonary rehabilitation
Year: 2019
COPD guides and inhaled corticosteroids. Is there an adequate use in primary care?
Source: International Congress 2016 – Targeting care, pulmonary rehabilitation, management, and self-management of COPD exacerbations in primary care
Year: 2016
Effects of pharmacist interventions to inhalation medication adherence and lung functions in COPD patients at one stop service clinic
Source: International Congress 2014 – COPD exacerbations
Year: 2014
Stepping-down inhaled corticosteroid therapy in stable asthma: a secondary care perspective
Source: Eur Respir J 2005; 26: Suppl. 49, 277s
Year: 2005
Omalizumab decreases medical resource utilisation in patients with severe allergic asthma in an Italian real-life setting
Source: International Congress 2017 – Asthma management
Year: 2017
Budesonide/formoterol for the treatment of COPD exacerbations in the primary healthcare setting
Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD
Year: 2008
Maintenance of long term benefits from an outpatient pulmonary rehabilitation programme in COPD
Source: Annual Congress 2011 - Challenges in rehabilitation: some old dilemmas revisited with some solutions?
Year: 2011
Patients with COPD prescribed inhaled corticosteroid in primary care – Time for re-assessment based on exacerbation rate and blood eosinophils?
Source: Virtual Congress 2020 – Diagnosis and management of airways disease in primary care
Year: 2020
Predicting physician decision to prescribe systemic corticosteroids following an exacerbation of airways disease
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Physician assessment of asthma control in patients receiving omalizumab in a real-world setting
Source: Annual Congress 2012 - Asthma treatment: efficacy and safety
Year: 2012
Expanding the scope of pulmonary rehabilitation
Source: Annual Congress 2005 - The ERS/ATS statements on pulmonary rehabilitation
Year: 2005
Patients’ perception of allergic asthma and their compliance to omalizumab in an Italian clinical setting
Source: International Congress 2017 – Asthma management
Year: 2017
Antibiotic effectiveness to prevent new chronic obstructive pulmonary disease (COPD) exacerbations in current medical practice
Source: Annual Congress 2009 - Functional insights into COPD
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept